Regulus Therapeutics Stock Buy Hold or Sell Recommendation
| RGLS Stock | USD 1.63 0.02 1.24% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Regulus Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Regulus Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Regulus Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Regulus Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide. Note, we conduct extensive research on individual companies such as Regulus and provide practical buy, sell, or hold advice based on investors' constraints. Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Regulus |
Execute Regulus Therapeutics Buy or Sell Advice
The Regulus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Regulus Therapeutics. Macroaxis does not own or have any residual interests in Regulus Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Regulus Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Regulus Therapeutics Trading Alerts and Improvement Suggestions
| Regulus Therapeutics may become a speculative penny stock | |
| Regulus Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (30.04 M) with loss before overhead, payroll, taxes, and interest of (18.41 M). | |
| Regulus Therapeutics currently holds about 47.53 M in cash with (26.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Regulus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Top TSX Penny Stocks To Watch In November 2024 |
Regulus Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Regulus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Regulus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Regulus Therapeutics Returns Distribution Density
The distribution of Regulus Therapeutics' historical returns is an attempt to chart the uncertainty of Regulus Therapeutics' future price movements. The chart of the probability distribution of Regulus Therapeutics daily returns describes the distribution of returns around its average expected value. We use Regulus Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Regulus Therapeutics returns is essential to provide solid investment advice for Regulus Therapeutics.
| Mean Return | 0.04 | Value At Risk | -6.41 | Potential Upside | 7.19 | Standard Deviation | 4.13 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Regulus Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Regulus Stock Institutional Investors
The Regulus Therapeutics' institutional investors refer to entities that pool money to purchase Regulus Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Alyeska Investment Group, L.p. | 2024-09-30 | 1 M | State Street Corp | 2024-09-30 | 1 M | Woodline Partners Lp | 2024-09-30 | 948.7 K | Dafna Capital Management Llc | 2024-09-30 | 895.2 K | Point72 Asset Management, L.p. | 2024-09-30 | 893.8 K | Ra Capital Management, Llc | 2024-09-30 | 766.8 K | Opaleye Management Inc | 2024-09-30 | 535 K | Northern Trust Corp | 2024-09-30 | 497.3 K | Cvi Holdings Llc | 2024-06-30 | 401 K | Federated Hermes Inc | 2024-09-30 | 12.9 M | Nea Management Company, Llc | 2024-09-30 | 6.5 M |
Regulus Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 20.2M | (3.0M) | 29.4M | (36.2M) | (461K) | (438.0K) | |
| Free Cash Flow | (20.1M) | (12.5M) | (24.4M) | (25.9M) | (27.4M) | (28.8M) | |
| Depreciation | 931K | 467K | 459K | 122K | 227K | 215.7K | |
| Other Non Cash Items | 2.1M | 154K | 46K | (52K) | (16K) | (15.2K) | |
| Capital Expenditures | 244K | 11K | 251K | 361K | 613K | 611.5K | |
| Net Income | (18.6M) | (15.7M) | (27.8M) | (28.3M) | (30.0M) | (31.5M) | |
| End Period Cash Flow | 34.1M | 31.1M | 60.4M | 24.3M | 23.8M | 28.1M | |
| Change To Netincome | 2.6M | 2.8M | 2.3M | 2.1M | 1.9M | 1.8M | |
| Change To Inventory | (606K) | 270.0 | 610.0 | 304.0 | 349.6 | 367.08 | |
| Investments | 74K | (11K) | (251K) | (15.1M) | 20.0M | 21.0M | |
| Net Borrowings | (3.3M) | (2.0M) | (10M) | (80K) | (72K) | (68.4K) | |
| Change Receivables | 1.3M | 347K | (1.1M) | 638K | 733.7K | 770.4K |
Regulus Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Regulus Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Regulus Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Regulus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.09 | |
β | Beta against Dow Jones | 0.94 | |
σ | Overall volatility | 4.11 | |
Ir | Information ratio | -0.02 |
Regulus Therapeutics Volatility Alert
Regulus Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regulus Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regulus Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Regulus Therapeutics Fundamentals Vs Peers
Comparing Regulus Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Regulus Therapeutics' direct or indirect competition across all of the common fundamentals between Regulus Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Regulus Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Regulus Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Regulus Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Regulus Therapeutics to competition |
| Fundamentals | Regulus Therapeutics | Peer Average |
| Return On Equity | -0.72 | -0.31 |
| Return On Asset | -0.42 | -0.14 |
| Current Valuation | 18.63 M | 16.62 B |
| Shares Outstanding | 65.5 M | 571.82 M |
| Shares Owned By Insiders | 1.69 % | 10.09 % |
| Shares Owned By Institutions | 88.29 % | 39.21 % |
| Number Of Shares Shorted | 1.64 M | 4.71 M |
| Price To Earning | (0.69) X | 28.72 X |
| Price To Book | 1.21 X | 9.51 X |
| Price To Sales | 7.43 X | 11.42 X |
| Gross Profit | (18.41 M) | 27.38 B |
| EBITDA | (30.88 M) | 3.9 B |
| Net Income | (30.04 M) | 570.98 M |
| Cash And Equivalents | 47.53 M | 2.7 B |
| Cash Per Share | 3.25 X | 5.01 X |
| Total Debt | 2.39 M | 5.32 B |
| Debt To Equity | 0.17 % | 48.70 % |
| Current Ratio | 8.82 X | 2.16 X |
| Book Value Per Share | 1.32 X | 1.93 K |
| Cash Flow From Operations | (26.77 M) | 971.22 M |
| Short Ratio | 3.63 X | 4.00 X |
| Earnings Per Share | (1.02) X | 3.12 X |
| Price To Earnings To Growth | (0.04) X | 4.89 X |
| Target Price | 10.33 | |
| Number Of Employees | 32 | 18.84 K |
| Beta | 1.63 | -0.15 |
| Market Capitalization | 107.42 M | 19.03 B |
| Total Asset | 30.75 M | 29.47 B |
| Retained Earnings | (513.21 M) | 9.33 B |
| Working Capital | 19.67 M | 1.48 B |
| Current Asset | 134.26 M | 9.34 B |
| Current Liabilities | 12.63 M | 7.9 B |
| Net Asset | 30.75 M |
Note: Acquisition by Nunn Jason Raleigh of 30000 shares of Regulus Therapeutics at 1.45 subject to Rule 16b-3 [view details]
Regulus Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Regulus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 8428.08 | |||
| Daily Balance Of Power | 0.2857 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 1.63 | |||
| Day Typical Price | 1.63 | |||
| Price Action Indicator | 0.015 | |||
| Period Momentum Indicator | 0.02 |
About Regulus Therapeutics Buy or Sell Advice
When is the right time to buy or sell Regulus Therapeutics? Buying financial instruments such as Regulus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Regulus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Penny Thematic Idea Now
Penny
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.